Novartis Ag Stock News

Vas Narasimhan. CEO at Novartis, discusses the future of Sandoz.

Vas Narasimhan, CEO at Novartis, joins CNBC as the company releases fourth-quarter earnings.

Novartis reported fourth-quarter core operating income gained 9% as higher drug sales offset in increase in marketing and development costs.

How to spend $45 billion is a nice problem to have. That's the sum Swiss pharmaceutical giant Novartis AG ( NVS , Financial) will have at its disposal if a rumored sale of its Sandoz unit materializes

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit NVS Sandoz, Bloomberg reports, citing people close to the matter.  Thousands of new tra

Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.

Private equity firms Blackstone Inc and Carlyle Group Inc are in talks about potentially teaming up on a bid for Swiss drugmaker Novartis' generics unit, Bloomberg News reported on Tuesday, citing peo

Amgen and Novartis have added an amendment to a licensing and collaboration agreement for the migraine medication Aimovig (erenumab).

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.

U.S. equity markets opened mixed on Monday, with the Dow Jones industrials lagging and the tech-heavy Nasdaq adding about 1.5% in the early going.

US Futures Start The Week With More Wild Swing In Another Volatile, Illiquid Session After a rollercoaster week that ended just barely higher following a late meltup on Friday, overnight volatile US stock futures swung to start the week, with Nasdaq 100 futures leading gains after rallying on Friday, before turning red and threatening to fizzle a global equity rally amid persistent worries over the Federal Reserve’s plan to hike interest rates this year. Emini S&P futures were down 0.5% or 21 points to 4401, after rising as high as 4437 and dropping as low as 4395 in another extremely illiquid session where China being offline for the week due to Lunar New Year did not help; Nasdaq futures were down 0.1% while Dow futures were lower 0.7%. Technology stocks led gains on the Stoxx Europe 600. Meanwhile, the dollar fell and oil rallied. As investors reconcile to a hawkish U.S. central bank coupled with strong earnings, the expensive parts of the U.S. stock market are undergoing a valuation re-rating along with the bond markets.

Volatility is back on Wall Street, with tech suffering its worst month since 2008. No one knows how long or deep the 2022 correction will be, but prudent risk-management, not market timing is your bes

Both of these businesses could also be good growth plays.

Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success